03 May 2022, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies targeting RNA epigenetic mechanisms, today announces that it has been awarded a Biomedical Catalyst grant by Innovate UK to research and develop new drugs directed against a unique SARS-CoV2 protein utilizing STORM’s proprietary RNA epigenetic platform.
STORM has established a novel drug discovery platform to enable the identification of first in class inhibitors targeting RNA-modifying enzymes for oncology, infection, and inflammatory diseases. The platform is…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF
AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING
- Demonstrates best-in-class potential for effective disease management in patients requiring high daily doses of insulin
- Delivers significantly accelerated absorption of insulin compared to gold standard, NovoRapid®(100U/mL), despite a 5-fold increase in concentration
- A critical enabler in the development of next generation miniaturised insulin-delivery systems
- Favourable safety profile…
Leading global drug development consultancy Boyds has appointed experienced clinical researcher Caroline Corbett as Director of Clinical Operations to support the team’s continued growth and the rising demand for its specialist clinical trial expertise.
As Director of Clinical Operations at Boyds, Caroline will support Dr Karen O’Hanlon, Vice President of Clinical Operations, with the ongoing growth and development of the clinical operations team and service offering.
Based at Boyds’ Cambridge office, Caroline will focus on the delivery of study start-up activities, including site selection…
Cambridge Innovation Capital (CIC), the venture capital investor focused on building world-leading deeptech and life sciences businesses connected with the Cambridge ecosystem, has raised £225 million ($300 million) for its oversubscribed second fund (Fund II).
CIC was founded to improve the success rate of businesses originating from the University of Cambridge and the broader Cambridge ecosystem, to encourage more academics and entrepreneurs from the area to build businesses. In addition to its portfolio companies, CIC has co-founded two Cambridge-based business accelerators, DeepTech Labs…
Cambridge, UK 25th April 2022– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Paul Beastall as Chair of the Board of Directors. Paul was previously a Non-Executive Director at Evonetix, having joined the Board in 2020. His new appointment to Chair will see him take a more involved role in guiding product development strategy. This announcement follows the Company’s recent patent grant for technology enabling thermally-controlled DNA synthesis. Paul has over 20 years’ experience in product…
Marks & Clerk are delighted to announce that Associates Graham McGlashan and Erik Rõuk will be attending the 7th International XR Conference, taking place in Lisbon next month.
The event is taking place in partnership with The Manchester Metropolitan University, ISCTE - Instituto Universitario de Lisboa and the International Association of Immersive Technology Innovation.
Graham will be participating in a discussion about how the Metaverse is reshaping society and also leading a talk about trends in XR-related patent filings; so this is definitely not an event to be missed.
For more…
Nottingham-based contract research organisation (CRO) Cellomatics Biosciences has today been recognised with one of the UK’s most prestigious business awards – the Queen’s Award for Enterprise for International Trade.
Cellomatics is one of 225 organisations nationally to be recognised with a prestigious Queen’s Award for Enterprise.
Employing 15 people, Cellomatics was founded in 2015 and specialises in the development of bespoke bioassays across numerous therapeutic areas including oncology, immuno-oncology, immunology, inflammation and respiratory.
Last year, the company reported year-on-…
Leading global drug development consultancy Boyds has bolstered its clinical team with the appointment of experienced pharmaceutical physician Dr Karen Mullen FFPM as Chief Medical Offer (CMO) and Vice President of Clinical and Medical Affairs.
Karen joins Boyds from GlaxoSmithKline, with her most recent role being Country Medical Director for the UK and Ireland in which she led and managed a large medical department across clinical research, pharma, and vaccines. Karen’s previous roles at GSK include Head of Medical Affairs, Director of Vaccines, and Director of Metabolic Medicine.
With…
Exciting One Nucleus and Future of Work Collaboration for Employer of Choice Series
Cambridge UK: 26 April 2022
One Nucleus is delighted to announce a unique collaboration with the Future of Work Institute to host 5 one-hour seminars for our Employer of Choice Series through 2022.
Aligning employer and employee needs, values and aspirations in the workplace produces many opportunities irrespective of company size or business model. The purpose of this collaboration is to provide our members with real world insights, guidance, and best practices on becoming employers of choice in order to…
One Nucleus Announce Exciting Collaboration with ProductLife Group on New Training Course: ‘Performance Evaluation & Post-Market Surveillance on Medical Devices & IVDs under MDR & IVDR’
Cambridge UK: 14 April 2022
As One Nucleus continues to develop its training portfolio to meet the needs of member and non-member companies and their employees, it is delighted to announce an exciting new collaboration with ProductLife Group (PLG).
In a changing regulatory environment, this two-day online course is an opportunity for those knowledgeable in Medical Device…